Considering the prolonged duration of intravenous treatment for HER2-positive breast cancer and the use of vesicant chemotherapy agents, different central venous access devices are often inserted for patients that may have so-called “difficult” veins or to prevent complications associated with peripheral vein access, such as extravasation, infiltration or phlebitis [52]. This evidence concerns the gene ERBB2 and breast cancer.